CNS Pharmaceuticals Files 2024 10-K

Ticker: CNSP · Form: 10-K · Filed: 2025-03-31T00:00:00.000Z

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

CNS Pharma filed its 2024 10-K. Full financials and ops details are in.

AI Summary

CNS Pharmaceuticals, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Nevada and headquartered in Houston, TX, operates in the pharmaceutical preparations sector. Key financial data and operational details for the fiscal year 2024 are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of CNS Pharmaceuticals' financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, CNS Pharmaceuticals faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in their 10-K filing.

Key Numbers

2024 — Fiscal Year (Reporting period for the 10-K)
2023 — Prior Fiscal Year (For comparative financial analysis)
2022 — Prior Fiscal Year (For comparative financial analysis)

Key Players & Entities

CNS Pharmaceuticals, Inc. (company) — Filer of the 10-K
2024-12-31 (date) — Fiscal year end
2025-03-31 (date) — Filing date
Houston, TX (location) — Company headquarters

FAQ

What is the primary business of CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted on March 31, 2025.

What fiscal year does this 10-K report cover?

This 10-K report covers the fiscal year ending December 31, 2024.

Where is CNS Pharmaceuticals, Inc. headquartered?

CNS Pharmaceuticals, Inc. is headquartered in Houston, TX.

What is the state of incorporation for CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is incorporated in Nevada (NV).

From the Filing

0001683168-25-002139.txt : 20250331 0001683168-25-002139.hdr.sgml : 20250331 20250331171145 ACCESSION NUMBER: 0001683168-25-002139 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250331 DATE AS OF CHANGE: 20250331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25794895 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 10-K 1 cns_i10k-123124.htm FORM 10-K FOR DEC 2024 CNS Pharmaceuticals, Inc. 10-K false 2024 FY 0001729427 0001729427 2024-01-01 2024-12-31 0001729427 2024-06-30 0001729427 2025-03-31 0001729427 2024-12-31 0001729427 2023-12-31 0001729427 2023-01-01 2023-12-31 0001729427 us-gaap:CommonStockMember 2022-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001729427 us-gaap:RetainedEarningsMember 2022-12-31 0001729427 2022-12-31 0001729427 us-gaap:CommonStockMember 2023-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001729427 us-gaap:RetainedEarningsMember 2023-12-31 0001729427 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001729427 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001729427 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001729427 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001729427 us-gaap:CommonStockMember 2024-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001729427 us-gaap:RetainedEarningsMember 2024-12-31 0001729427 2024-06-03 2024-06-04 0001729427 2024-11-25 2024-11-26 0001729427 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-12-31 0001729427 CNSP:UnvestedPerformanceUnitsMember 2024-01-01 2024-12-31 0001729427 CNSP:OptionsMember 2024-01-01 2024-12-31 0001729427 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2023-01-01 2023-12-31 0001729427 CNSP:UnvestedPerformanceUnitsMember 2023-01-01 2023-12-31 0001729427 CNSP:OptionsMember 2023-01-01 2023-12-31 0001729427 us-gaap:LeaseholdImprovementsMember 2024-01-01 2024-12-31 0001729427 us-gaap:ComputerEquipmentMember 2024-12-31 0001729427 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001729427 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001729427 CNSP:November2024NoteMember 2024-11-28 0001729427 CNSP:November2024NoteMember 2024-11-27 2024-11-28 0001729427 CNSP:November2024NoteMember 2024-12-31 0001729427 CNSP:November2023NoteMember 2023-11-28 0001729427 CNSP:November2023NoteMember 2023-11-27 2023-11-28 0001729427 CNSP:November2023NoteMember 2024-12-31 0001729427 CNSP:November2023NoteMember 2023-12-31 0001729427 us-gaap:CommonStockMember 2024-05-01 0001729427 us-gaap:CommonStockMember 2024-12-31 0001729427 2024-05-01 0001729427 CNSP:EquityPlan2020Member 2024-04-30 0001729427 us-gaap:SubsequentEventMember 2025-02-20 2025-02-21 0001729427 CNSP:January2024PublicOfferingMember us-gaap:CommonStockMember 2024-01-28 2024-01-29 0001729427 CNSP:January2024PublicOfferingMember CNSP:PreFundedWarrantsMember 2024-01-28 2024-01-29 0001729427 CNSP:January2024PublicOfferingMember CNSP:SeriesAWarrantsMember 2024-01-28 2024-01-29 0001729427 CNSP:January2024PublicOfferingMember CNSP:SeriesBWarrantsMember 2024-01-28 2024-01-29 0001729427 CNSP:January2024PublicOfferingMember CNSP:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001729427 CNSP:January2024PublicOfferingMember 2024-01-28 2024-01-29